Topic: myeloma

Revlimid bottle

1. Revlimid

Revlimid has been on the market for a decade, and it's been the powerhouse behind Celgene's growth since its launch. Already a megablockbuster, the drug is the linchpin of a hematology franchise that Celgene expects to exceed $15 billion in annual revenue by 2020, with Revlimid sales forecast to more than double by 2022.